Andecaliximab (INN;[1] development code GS-5745) is an experimental humanized monoclonal antibody designed for the treatment of cancer and inflammatory diseases.

This drug was developed by Gilead Sciences, Inc.[2]

Phase II and phase III trials for gastric cancer or gastroesophageal junction adenocarcinoma completed in 2019.

References

  1. ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Andecaliximab, American Medical Association.
Allikas: https://en.wikipedia.org/wiki/Andecaliximab
No tags for this post.